BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Treatment
6 results:

  • 1. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
    Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
    Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Identification of an AP1-ZFP36 Regulatory Network Associated with Breast Cancer Prognosis.
    Canzoneri R; Naipauer J; Stedile M; Rodriguez Peña A; Lacunza E; Gandini NA; Curino AC; Facchinetti MM; Coso OA; Kordon E; Abba MC
    J Mammary Gland Biol Neoplasia; 2020 Jun; 25(2):163-172. PubMed ID: 32248342
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dihydrotestosterone promotes kidney cancer cell proliferation by activating the stat5 pathway via androgen and glucocorticoid receptors.
    Pak S; Kim W; Kim Y; Song C; Ahn H
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2293-2301. PubMed ID: 31401673
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
    J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Transforming growth factor-beta downregulates interleukin-2-induced phosphorylation of signal transducer and activator of transcription 5 in human renal cell carcinoma.
    Song C; Jun SY; Hong JH; Ahn H
    J Cancer Res Clin Oncol; 2007 Jul; 133(7):487-92. PubMed ID: 17279417
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.